ClinicalTrials.gg
RecruitingNCT06120647Updated Dec 11, 2023

Molecular Mechanisms Underpinning Sarcopenic Obesity

An observational study in Sarcopenic Obesity, Obesity and Sarcopenia, sponsored by The Swedish School of Sport and Health Sciences. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by The Swedish School of Sport and Health Sciences · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 179 studies in Obesity with a site in Sweden — 38 open to participants now, 49 under way, 8 of them phase 3. Obesity · Sweden.

Planned enrollment
20th of 30
60 · median 103
Started
2020
with 5 others
Observational
30 of 179
9 open now
Primary completion
2025-12
later than 11 of 48 live
Registered
147th of 179
by date

Among the 179 studies in Obesity with a site in Sweden, this one is the 20th largest by planned enrollment of the 30 observational ones that give a count, is one of 6 that started in 2020, is one of 30 observational ones, reaches primary completion later than 11 of the 48 other live ones, and was the 147th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

38 of the 179 studies in Obesity with a site in Sweden are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Obesity with a site in Sweden, or all of them as a file.
02

Study summary

The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.

03

Conditions studied

  • Sarcopenic Obesity
  • Obesity
  • Sarcopenia
  • Aging
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The elderly participants will be community-dwelling living in the greater Stockholm metropolitan area. Participants will be recruited through local senior clubs, online communities, advertisement and word of mouth.

The young participants will be living in the greater Stockholm metropolitan area. Participants will be recruited through university forums, online communities, advertisement and word of mouth.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body fat % in accordance with previously defined criteria
  • Free of smoking (since 10 years)
  • Able to walk without assistance
  • Able to perform bilateral leg extension exercise

Exclusion criteria

Exclusion Criteria:

  • History of or present disease of myocardial, vascular, endocrine, hepatic, renal, pulmonary or neuromuscular origin
  • Uncontrolled hypo/hypertension
  • Use of anticoagulants (Warfarin, Trombyl)
  • Use of metformin or other anti-diabetic medications
  • Poor appetite and unexplained weight loss (4,5 kg) over the past 6 months
  • Active
  • Present infection
  • Dementia or delirium
  • Other conditions that may interfere with the study protocol in the opinion of the PI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Sarcopenic obesity

    Age: 70-80 years Men, ALM/W \< 25.7 %, body fat % \> 35 Women, ALM/W \< 19.7 %, body fat % \> 40

    Dietary Supplement: Essential amino acids (EAA)

  • Non-sarcopenic obese

    Age: 70-80 years Men, ALM/W \> 25.7 %, body fat % \> 35 Women, ALM/W \> 19.7 %, body fat % \> 40

    Dietary Supplement: Essential amino acids (EAA)

  • Non-sarcopenic lean

    Age: 70-80 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32

    Dietary Supplement: Essential amino acids (EAA)

  • Young lean

    Age: 18-40 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32

    Dietary Supplement: Essential amino acids (EAA)

Interventions

06

What researchers measure

Primary outcomes

  1. Fiber type-specific cell signalling

    This measure will be investigated during an experimental trial in which the participants are subjected to an acute bout of resistance exercise followed by the ingestion of essential amino acids (240 mg/kg lean mass). During this 3 hour time period, the participants will donate two muscle biopsies, one before exercise and the second one 1 hour after exercise. Cell signalling networks related to muscle mass regulation will be examined in these biopsy samples. The signal will be measured using Western blotting and the signal obtained is expressed in relation to baseline (adjusted volume intensity).

    Time frame: 1 hour after ingestion of essential amino acids and resistance exercise

Secondary outcomes

  1. Skeletal muscle fiber characteristics

    Fiber type-specific area measured using immunofluorescence microscope in muscle biopsies collected at baseline (prior to ingestion of essential amino acids and resistance exercise). Unit of measurement is square micrometers (µm\^2).

    Time frame: 1 hour prior to ingestion of essential amino acids and resistance exercise

  2. Whole body muscle volume

    Indices of muscle volume and fat infiltration obtained with magnetic resonance imaging (MRI). Unit of measurement is cubic centrimeters (cm\^3).

    Time frame: 1 hour

  3. Whole body glucose tolerance

    Oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood glucose levels will be monitored throughout a period of 2 hours. Unit of measurement is mmol/L glucose.

    Time frame: 2 hours

  4. Accelerometer-assessed physical activity levels

    Hip-worn accelerometer data (Actigraph GT3X) collected over 7 consecutive days. Unit of measurement is steps per day.

    Time frame: 1 week

  5. Isometric and isokinetic leg muscle strength

    Muscle performance will be evaluated at a single timepoint during the study using IsoMed2000 dynamometer. Participants will perform a maximal isometric contraction at 60 degrees of knee flexion. Unit of measurement is Newton meter (N-m).

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Dec 2025, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Nov 7, 2023
StartActual
Jan 28, 2020
Primary completionEst.
Dec 15, 2025
CompletionEst.
Dec 30, 2025
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06120647
Lead sponsor
The Swedish School of Sport and Health Sciences
Responsible party
William Apro (Associate Professor, The Swedish School of Sport and Health Sciences) — Principal investigator
First posted
Nov 7, 2023
Start date
Jan 28, 2020
Primary completion
Dec 15, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Dec 11, 2023

Study contacts

William Apró, PhD
Contact
william.apro@gih.se
08-120 538 67 ext. +46
William Apró, PhD
principal investigator · The Swedish School of Sport and Health Sciences and Karolinska Institute, Stockholm Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion